Amgen Stock Holds Near 52-Week High After Earnings Beat

Amgen stock has held near its 52-week high after beating earnings expectations and issuing updated full-year guidance. The biotechnology company posted non-GAAP earnings per share of $6.29 for its latest quarter, exceeding analysts' consensus estimates by $0.67.

This marks a year-over-year increase from $6.02 in the same quarter last year. Management has also set full-year 2026 EPS guidance between $22.300 and $23.500, higher than the current analyst forecast of $22.78 for the year.

An insider sale of shares valued at $521,370.36 drew attention to Amgen's strong run, but this move does not necessarily signal weakening confidence in the stock. Rather, it highlights how far the stock has climbed relative to its own recent history.